SCHEMBL9944362

SCHEMBL9944362

CC(C)OC(=O)c1cc2ccccc2c2cccnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 7/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HPGD P15428 2/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
ELANE P08246 1/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTT P42858 1/20 0.41
CA12 O43570 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9945608 0.85 KDM4E (0.57) KDM4EALDH1A1HPGDRAB9AKMT2A
SCHEMBL9944361 0.79 ALDH1A1 (0.60) KDM4EALDH1A1NPC1RAB9AKMT2A
SCHEMBL9944363 0.76 PDE4A (0.51) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL27695227 0.76 CA12 (0.55) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL9944372 0.75 KDM4E (0.52) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL6227794 0.74 MEN1 (0.60) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL30938001 0.74 ALDH1A1 (0.54) KDM4EALDH1A1CYP1A2LMNAL3MBTL1
SCHEMBL18943844 0.74 ALDH1A1 (0.54) KDM4EALDH1A1CYP1A2LMNAL3MBTL1
SCHEMBL16291327 0.73 RAB9A (0.52) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL6824375 0.73 ALDH1A1 (0.47) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846291-B2 Resist composition, method of forming resist pattern, and new compound TOKYO OHKA KOGYO CO. LTD. (JP) 2014-09-30 US disclosed
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND C1R, SLC11A2, RER1 KDM4E 4730/4885ALDH1A1 2007/4885CYP1A2 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.